Native GnRH · fertility & diagnostics
Gonadorelin is a synthetic copy of gonadotropin-releasing hormone (GnRH, also called LHRH), the 10-amino-acid signal the hypothalamus sends to the pituitary to release reproductive hormones. It has been used to probe pituitary function and, delivered in pulses by a small pump, to restore fertility when the body's own GnRH signal is missing.
The hypothalamus releases GnRH in pulses, and the pituitary answers each pulse by releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drive the ovaries and testes. The rhythm matters. In classic experiments in monkeys whose own gonadotropin release had been abolished by brain lesions, intermittent pulses of synthetic GnRH restored LH and FSH release, whereas a constant infusion failed to and could switch the response off, a process called desensitization or down-regulation3. Pump-delivered gonadorelin therefore imitates the missing hypothalamic signal in people whose GnRH is absent or deficient4,5. Continuous exposure tends to suppress the same axis instead3.
Most human evidence concerns pulsatile treatment of hypogonadotropic hypogonadism, in which the brain does not produce enough GnRH. A 2018 meta-analysis of 35 studies in 1,002 women with hypothalamic amenorrhea, mostly observational, found high ovulation rates, a low rate of mild ovarian hyperstimulation, and a multiple-pregnancy rate slightly above that of the general population4.
In men with congenital hypogonadotropic hypogonadism, a 2021 meta-analysis of seven comparative studies (420 men) found pulsatile GnRH associated with larger testes and earlier sperm production than gonadotropin injections, with similar overall sperm and pregnancy rates; the authors called for better randomized trials5. Gonadorelin is also used in diagnostic stimulation tests; in one clinic series of 234 girls, central precocious puberty was diagnosed from the LH peak after gonadorelin stimulation6. A PubMed search found no controlled trials of gonadorelin given alongside testosterone therapy.
FDA approved gonadorelin hydrochloride (Factrel) in 1982 and gonadorelin acetate (Lutrepulse kit, an orphan product) in 1989; both are listed as discontinued, so no FDA-approved gonadorelin product for human use is currently marketed in the US1,2.
In men, allergic reactions were reported more often with pump-delivered GnRH than with gonadotropin injections5; in women, ovarian hyperstimulation was uncommon and mild, multiple pregnancies were somewhat more frequent than usual, and intravenous pumps were rarely linked to vein inflammation (thrombophlebitis)4. Published human data on other, off-label patterns of use are scarce.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.